SIA
GEVA

Sit Investment Associates’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Sit Investment Associates’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,825
Closed -$568K – 516
2015
Q1 		$568K Sell
5,825
-3,900
-40% -$413K 0.01% 350
2014
Q4 		$902K Sell
9,725
-730
-7% -$57.6K 0.02% 320
2014
Q3 		$719K Sell
10,455
-5,300
-34% -$380K 0.01% 350
2014
Q2 		$1.65M Hold
15,755
– – 0.03% 303
2014
Q1 		$1.31M Buy
+15,755
New +$1.46M 0.02% 326

Sit Investment Associates's GEVA Position: Q2 2015 in Review

Sit Investment Associates sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 5,825 shares — an estimated $568K sold.

Sit Investment Associates first reported a position in GEVA in Q1 2014 and held it in 5 quarters. The position peaked at $1.65M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Sit Investment Associates reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Sit Investment Associates sold 5,825 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $568K.
  • Sit Investment Associates first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 5 quarters.
  • Sit Investment Associates's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.65M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Sit Investment Associates's 13F filing for Q2 2015, filed 20 Jul 2015.